All News

The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.

The use of a novel drug combination yielded positive outcomes in patients with B-cell lymphomas for whom CAR-T cell therapy or stem cell transplant isn’t an option.

Most patients with acute myeloid leukemia and myelodysplastic syndrome achieved strong antibody responses to COVID-19 vaccination, according to recent study results.

Treatment with Ninlaro plus Darzalex and a low dose of the steroid dexamethasone was associated with favorable responses to treatment in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.

A cancer survivor explains how his holiday traditions changed after his wife was sick with and eventually died from cancer, and why each changing tradition holds a special place in his heart.

For patients with neuroendocrine tumors that have spread, curating a liver-directed approach may make their treatment process less risky and less invasive, according to an expert.

Patients with chronic lymphocytic leukemia reported improved quality of life when treated with frontline Imbruvica and Rituxan, followed by continuous treatment with Imbruvica.

The immunotherapy Kymriah offered similar benefits in patients younger than and older than 18 years with relapsed/refractory B-cell acute lymphoblastic leukemia.

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

Although patients treated with Lynparza after chemotherapy may experience side effects such as fatigue and nausea/vomiting, these symptoms resolved after treatment was completed in patients with high-risk early breast cancer.

A three-drug regimen was shown to lengthen the amount of time before cancer progressed to the central nervous system — known as central nervous system progression-free survival — in certain patients with breast cancer.

In recent trial results, a dose reduction of Xpovio (selinexor) was associated with longer progression-free survival and duration of response while also reducing side effects in patients with multiple myeloma.

A patient with metastatic breast cancer reflects on the difficulties she faced in 2021 and why a shipwreck is the perfect metaphor for her year.

The use of pyrotinib — an experimental drug — plus the chemotherapy capecitabine extended survival compared with Tykerb and capecitabine among patients with pretreated HER2-positive metastatic breast cancer.

From the death of Nick Cannon’s five-month-old son due to brain cancer to the late-stage diagnosis of Kansas City reporter Matt Stewart’s wife, here’s what’s happening in the cancer landscape this week.

Early-phase study results showed that treatment with a novel drug elicits promising outcomes in patients with advanced or metastatic triple-negative breast cancer.

Clinical trial results show that adding Keytruda to chemotherapy prior to surgery for triple-negative breast cancer can improve outcomes and hopefully “increase the chances for patients to be cured,” according to an expert.

Treatment modifications in the pre-surgery setting led to a lower rate of pathologic complete response in Black patients with breast cancer, the researchers found.

Oftentimes the warmest holiday moments can remind cancer survivors of how much their paths have been derailed, a survivor explains.

On this episode of the “Cancer Horizons” podcast, a woman with multiple myeloma shares how she made the best of her cancer treatment process by channeling her emotions through fashion expression.

The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.

Amma was developed by a cancer survivor who wanted an easier — and cheaper — way for patients to preserve their hair during chemotherapy treatment.

CURE®’s second episode of its cooking show, Heal at Home, is here! And this time, we are bringing cancer survivors, patients and their loved ones the nutrition with a dash of holiday cheer.

Each time a new COVID-19 variant takes the world by storm, cancer survivors struggle to cope with the resulting exhaustion and fear, one survivor explains.

Researchers hypothesized that metformin — a medication that helps lower insulin levels in patients with diabetes and is associated with inducing weight loss — might improve breast cancer outcomes.

The use of elacestrant, an investigational therapy, elicited a 30% reduction in the risk of disease progression or death compared with standard of care in a group of patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.

Ibrance plus Faslodex improved progression-free survival in certain patients with metastatic breast cancer, compared with those who continued to receive an aromatase inhibitor.

Frail patients older than 70 years who underwent geriatric assessment and received pertinent advice related to those results were more likely to have high-quality conversations with their oncologists about age-related concerns like physical activity and cognition.